Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: ART in Pregnancy

Source: Key Decisions in HIV Care
In this on-demand recording of a live webinar, expert faculty review key considerations for the use of ART in pregnancy. Topics include current recommendations and a discussion of the data to support ART options during pregnancy.
person default
Milena Murray, PharmD, MSc, BCIDP, AAHIVP
Jonah Musa, MBBS, MSCI, PhD
Released: November 8, 2021

In this episode from the series “Key Decisions in HIV Care,” Milena Murray, PharmD, MSc, BCIDP, AAHIVP, and Jonah Musa, MBBS, MSCI, PhD, discuss important considerations for ART use in pregnancy, including DHHS and WHO guideline recommendations and data supporting recommended ART regimen options in pregnancy from IMPAACT 2010, Tsepamo, and DoLPHIN-2. They also discuss pharmacokinetic  considerations and drug–drug interactions. Following their dialogue, the faculty field questions from healthcare professionals.

Information on this Educational Activity

Faculty

Milena Murray, PharmD, MSc, BCIDP, AAHIVP

Associate Professor
Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
HIV/ID Clinical Pharmacist
Pharmacy
Northwestern Memorial Hospital
Chicago, Illinois

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, has disclosed that she has received consulting fees from Theratechnologies and ViiV and fees for non-CME/CE services from Merck.
Jonah Musa, MBBS, MSCI, PhD

Professor, Obstetrics and Gynecology
University of Jos
Honorary Consultant Obstetrician and Gynecologist
Jos University Teaching Hospital
Jos, Nigeria

Jonah Musa, MBBS, MSCI, PhD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

From Clinical Care Options (CCO): Dr. Samantha Hill and Dr. David Malebranche on barriers to HIV testing, prevention, and treatment services in BIPOC communities and migrant populations in the US

person default Samantha V. Hill, MD, MPH David Malebranche, MD, MPH Released: January 12, 2022

Free slides from CCO featuring data on racial inequities in HIV care in BIPOC communities and strategies to combat racial disparities in HIV

person default Solange L. Baptiste, ScM Rageshri Dhairyawan, MBBS, BSc, FCRP, DipGUM, DipHIV, DFSRH person default Samantha V. Hill, MD, MPH David Malebranche, MD, MPH Released: January 11, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings